Blog
Something inspiring would go here to explain the blog.
-
Advancing made-in-B.C. health technology to strengthen patient care
By
Why This Matters: Modernizing care delivery can help improve the health system and patient access. British Columbia is helping companies pilot innovative technologies that could revolutionize healthcare delivery, support the
-
The mindset shift that could transform Canadian health care
By
Why This Matters: Protecting Canada’s health future means strengthening both patient outcomes and the economy. At a recent University of Waterloo event, former politician and executive chairman of Baylis Medical
-
Most Favored Nation Drug Pricing: Analysis and Implications
By
Why This Matters: As countries compete to attract research investment and secure early access to innovative medicines, understanding global pricing dynamics is critical to protecting Canada’s health future. This article
-
Walking a tightrope: Navigating US most-favored-nation prescription drug pricing in Canada
By
Why This Matters: As global markets adjust their drug policies, Canada faces growing competition for pharmaceutical investment and innovation. Understanding how these global drug policies interact with Canada’s domestic health
-
Medtech Canada advocates for “zero for-zero” tariffs to safeguard affordability and supply of medical technologies in Canadian health care
By
Why This Matters: Tariffs on medical technologies can drive up healthcare costs, limit the availability of essential equipment, and delay care for patients who need timely treatment. Keeping these products
-
‘An urgent public health crisis:’ Why so many people are struggling to get medicine
By
Why This Matters: When global supply chains falter, Canadian patients can face drug delays or cost increases. A resilient system means better access, less disruption, and fewer surprises in care.
-
Think Tank Calls on Ottawa to Abandon Single-payer Pharmacare Model
By
Why This Matters: A pharmacare model that removes existing coverage could leave many Canadians without the medicines they currently rely on. Canadians deserve a system that expands access, not one
-
Waiting for New Medicines in Canada, Europe, and the United States
By
In this article by the Canadian Health Policy Institute, readers learn that Canadians wait far longer than patients in the U.S. or Europe to access newly approved medicines. Submission delays,
-
Health Canada to Modernize Biologic Drug Submission
By
In this article by Torys LLP, they explain an announcement from Health Canada that makes it easier and faster for new biologic and biosimilar medicines to be approved. The updated
-
Health and Life Sciences M&A in the Waiting Room as Tariff and Economic Uncertainty Grow
By
In this article by Zena Olijnyk for Lexpert, readers see how U.S. tariff threats and economic uncertainty are putting Canadian health and life sciences dealmaking on hold. Buyers and sellers